Clinical Impact of New Data From ICAAC, IDWeek, and EACS 2013*

September 10-October 19, 2013; Denver, Colorado; San Francisco, California; Brussels, Belgium
Capsule summaries and a CME-certified slide deck

Clinical Impact of Data From HIV Conferences

Capsules

Both regimens yielded high virologic response rates at 48 weeks; the tenofovir alafenamide regimen continued to show fewer effects on renal function and bone mineral density.

Released: October 25, 2013

Among HIV-infected patients receiving antiretroviral therapy in an ACTG clinical trial, the risk of attempted or completed suicide was 2.5-fold higher among those assigned to efavirenz-containing regimens.

Released: October 25, 2013

High levels of efficacy maintained with little additional toxicity or resistance with the elvitegravir regimen between Weeks 96 and 144

Released: October 25, 2013

Higher rate of virologic suppression < 50 copies/mL at Week 48 with dolutegravir (90% vs 83%; P = .025) was largely driven by fewer withdrawals due to AEs or other reasons in the dolutegravir arm

Released: October 25, 2013

Single-tablet integrase inhibitor regimen showed durable efficacy and safety vs currently preferred regimens.

Released: October 25, 2013

Virologic failure at Week 48 was infrequent in previously untreated patients receiving lopinavir/ritonavir with either 1 or 2 NRTIs and was not associated with the emergence of PI resistance.

Released: October 23, 2013

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?